# OnCo record ev-304 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ev-304/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ev-304", "NCT04700124" ;
  schema:name "EV-304 / KEYNOTE-B15"@en ;
  schema:alternateName "EV-304"@en, "KEYNOTE-B15"@en ;
  schema:description "The trial that could replace chemotherapy before bladder removal in fit patients with an ADC plus immunotherapy."@en ;
  schema:url <https://onco.cc/trials/ev-304/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04700124>, <https://www.onclive.com/view/perioperative-enfortumab-vedotin-pembrolizumab-meets-efs-os-pcr-end-points-in-cisplatin-eligible-mibc> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-04-21" ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/astellas/> .